Critical Survey: Aktis Oncology (AKTS) vs. Its Rivals

Aktis Oncology (NASDAQ:AKTS) is one of 845 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Aktis Oncology to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Profitability

This table compares Aktis Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Aktis Oncology Competitors	-12,283.59%	-195.39%	-30.85%

Earnings and Valuation

This table compares Aktis Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aktis Oncology	$10.06 million	-$63.73 million	-20.78
Aktis Oncology Competitors	$727.63 million	$11.88 million	-18.06

Aktis Oncology’s peers have higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aktis Oncology and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1	0	9	1	2.91
Aktis Oncology Competitors	9902	15278	45630	1595	2.54

Aktis Oncology currently has a consensus price target of $35.62, indicating a potential upside of 109.07%. As a group, “Biotechnology” companies have a potential upside of 120.42%. Given Aktis Oncology’s peers higher probable upside, analysts clearly believe Aktis Oncology has less favorable growth aspects than its peers.

Insider & Institutional Ownership

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aktis Oncology Company Profile

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.